Prophylactic donor lymphocyte infusions after first allogeneic hematopoietic stem cell transplantation in children with acute leukemia [0.03%]
急性白血病儿童第一次异基因造血干细胞移植后的预防性供者淋巴细胞输注
Ang Wei,Chenguang Jia,Guanghua Zhu et al.
Ang Wei et al.
Purpose: To evaluate the feasibility and safety of prophylactic donor lymphocyte infusion (DLI) following allogeneic hematopoietic stem cell transplantation (HSCT) to improve survival outcomes in pediatric patients with a...
Plasma interleukin-12 levels as a potential biomarker of fatigue and quality of life in patients with primary immune thrombocytopenia [0.03%]
原发性免疫性血小板减少症患者细胞因子IL-12作为评估疲乏及生活质量潜在生物标志物的研究
Sarthak Wadhera,Arihant Jain,Aarushi Sahni et al.
Sarthak Wadhera et al.
Background: Fatigue significantly affects health-related quality of life (HRQoL) in patients with immune thrombocytopenia (ITP). However, the interplay between fatigue and cytokines in ITP remains poorly understood. ...
Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin's lymphoma [0.03%]
布伦妥木单抗联合顺铂、阿糖胞苷和地塞米松治疗适合移植的韩国复发或难治性霍奇金淋巴瘤患者的效果研究
Jun Ho Yi,Young Hoon Park,Myung-Won Lee et al.
Jun Ho Yi et al.
Purpose: Brentuximab vedotin (BV)-based combinations have shown promising results in patients with relapsed or refractory Hodgkin's lymphoma (RRHL) in Western countries. We conducted a phase II study to further define the...
Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma: bispecific antibodies and CAR T-Cell therapies [0.03%]
复发/难治滤泡性淋巴瘤的当前免疫治疗方法：双特异性抗体和CAR-T细胞疗法
So Yeon Park,Gi-June Min
So Yeon Park
Chemoimmunotherapy (CIT) combines anti-CD20 monoclonal antibodies with chemotherapy and has long been the standard first-line treatment for follicular lymphoma (FL). However, a significant subset of patients, particularly those who experien...
A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis [0.03%]
一项基于真实世界数据的分析：对比评估罗特西韦干扰素阿尔法-2б对羟基脲耐药或不耐受的真性红细胞增多症患者的血液学反应的比较研究
Sung-Eun Lee,Seug Yun Yoon,Sung-Yong Kim et al.
Sung-Eun Lee et al.
Purpose: To compare the hematologic response to ropeginterferon alfa-2b versus available therapies in patients with hydroxyurea-resistant or intolerant polycythemia vera (HU-R/I PV) using propensity-matched real-world dat...
Durable responses and favorable cost-effectiveness of rituximab-based chemoimmunotherapy for primary cold agglutinin disease [0.03%]
利妥昔单抗为基础的化疗免疫治疗原发性冷凝集素病的持久应答及良好的性价比
Kenichi Ito,Tomoko Kitagawa,Saya Motohashi et al.
Kenichi Ito et al.
Beyond anemia: unraveling neutrophil defects and infection susceptibility in β-Thalassemia [0.03%]
从贫血出发：揭示β-地中海贫血患者的中性粒细胞缺陷和易感感染的机制
Chingiz Asadov,Gunay Aliyeva
Chingiz Asadov
β-Thalassemia is characterized by defective β-globin synthesis and chronic transfusion dependence. Beyond anemia and iron overload, patients with β-thalassemia display heightened susceptibility to infections. Neutrophil granulocytes (NGs...
Early CD4 + T cell immune reconstitution as a biomarker for Epstein-Barr virus control following allogeneic transplantation [0.03%]
同种异体移植后早期CD4+T细胞免疫重建作为Epstein-Barr病毒感染的生物标志物
Kexin Lin,Wenwen Yang,Jiaxiu Yin et al.
Kexin Lin et al.
Purpose: Achieving high-quality immune reconstitution (IR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is directly associated with the patient's ability to resist infections, prevent tumor relapse...
Unveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia: a comprehensive review [0.03%]
微小核糖核酸、PI3K/AKT通路及其在各种类型白血病中的相互作用：综合述评
Amir Modarresi Chahardehi,Esfandiar Mali,Arya Afrooghe et al.
Amir Modarresi Chahardehi et al.
The phosphatidylinositol-3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and microRNA (miRNA) regulation have been implicated in the initiation and progression of acute leukemia. Despite significant progress in the unders...
Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study [0.03%]
伴有微量残留病变多发性骨髓瘤患者自体干细胞移植的串联 transplantation
Sieun Oh,Sung-Soo Park,Jung Yeon Lee et al.
Sieun Oh et al.
Purpose: Tandem autologous stem cell transplantation (tASCT) is a viable option for high-risk multiple myeloma (MM) patients. Minimal residual disease (MRD), a real-time surrogate marker of disease burden, serves as a val...